Audrey’s Selected Meeting List for February 2008
The BioSpace Career Fair , Monday, Feb. 4, 2008
Topic: Biotech Bay Career Fair
Date and Time: Monday, February 4, 2008, from 2 pm to 7 pm
Location: San Francisco Airport Marriott in Burlingame, California.
Register at:
http://careers.biospace.com/Jobs/Public/CareerReceptionDetails.aspx?RECEPTION_ID=
131&source=373
Do not miss the chance to interview with the biotechnology, pharmaceutical, medical
device and diagnostics industries' most prestigious companies!
Hundreds of positions are available with industry leaders such as:
All candidates must have at least a four-year college degree and two years of industry
related work experience to attend. (Equivalent work experience may be considered in lieu
of a four-year college degree.)
Qualified candidates will receive their invitations and confirmation numbers via email 24
to 48 hours after their resumes have been submitted. Pre-screened and accepted
candidates must bring a copy of their invitation with confirmation number to the event.
BioSpace Career Fair Team
888-750-4473
Chinese Bioscience Association BioEntrepreneur Event, Monday Evening, Feb. 4,
2008
Topic: “Building a Global Active Pharmaceutical Ingredient Company in Asia -- The
ScinoPharm Story”
Speaker: Dr. Jo Shen, Ph.D., Co-Founder, CEO and President of ScinoPharm Taiwan
Ltd.
Date and Time: Feb. 4, 2008, Monday, 6:30-9:30 PM
Venue: Fenwick & West LLP, Silicon Valley Center, 801 California St. Mountain View,
CA94041
This event is free for CBA members. $10 for non-members. $15 at the door. Register
http://www.cbasf.org/
Overview of Talk
When Dr. Shen and her partners first opened their Taipei office in 1997 to begin
gathering investment resources and potential customers for their business plan, they knew
their vision was worldwide and future focused. After toughing it out through eight
profitless years, the company is looking to cash in on the rapidly expanding oncology
market. Dr. Shen will recount the foresight and meticulous planning of her team in
keeping with the courageous movement onto the world stage.
Speaker Bio
Feb. 7, 2008
1
Dr. Shen is the Founder, CEO and President of ScinoPharm Taiwan, Ltd. a global
pharmaceutical company with world-class R&D and manufacturing facilities in Taiwan
and China for the development and manufacture of active pharmaceutical ingredients
meeting international GMP standards. ScinoPharm has raised a total capital investment of
US $ 170 M. Prior to ScinoPharm, Dr. Shen was a Pharmaceutical Consultant developing
global pharmaceutical manufacturing strategies, CEO and Founder of ScinoPharm US,
and previously Corporate VP, Corporate Operations & Technology Transfer at Syntex
Pharmaceutical Corporation. Dr. Shen graduated from Lehigh University (PhD) and
National Taiwan University (BS).
Bio2Device Group, Tuesday Morning, Feb. 5, 2008
Speaker: David McNinch, Senior Director of Marketing, Affymax, Inc.
Topic: “Big Pharma, Big Biotech, and Small BioPharma –
Career Considerations for Commercial Professionals”
Date and Time: Tuesday, Jan. 15, 8:30 am to 10:30 am
Location: NOVA, 505 West Olive, Sunnyvale, Room 510
Cost: Free
See details at www.bio2devicegroup.org
Topic Description
This talk will provide the perspective of a commercial professional who has worked
across the different environments. How does one consider career satisfaction and
advancement? What are the financial opportunities and risks? How much fun are you
having? These are all questions that come into play navigating the waters. David will
provide his views and observations on these issues.
Speaker Bio
David McNinch is Senior Director of Marketing for Affymax, Inc. in Palo Alto where he
focuses on building the commercial strategy and infrastructure needed to support their
Phase III product Hematide. David started and developed his career in Big Pharma at
AstraZeneca for 12 years with various roles in sales and commercial management. Just
prior to joining Affymax, David spent the past two and a half years working at Genentech
leading the marketing teams and commercial strategy for Nutropin and Pulmozyme.
BioEntrepreneur to BioEntrepreneur (BioE2E), Wednesday Evening, Feb. 6, 2008
Topic: “Early Stage Drug Development, A Balance of Luck and Perseverance: Herceptin
A Case Study”
Speaker: Cori Gorman, Ph.D., M.B.A., Principal, DNA Bridges, Inc.
Location: Wilson Sonsini Goodrich Rosati, 950 Page Mill Road, Palo Alto
Date and Time: Wednesday, February 6th, 6:45pm networking, 7:30pm panel
discussion
Register online at http://www.acteva. com/go/bioe2e before Monday, February
4, at 6pm to get the pre-registration price of $25.
On-site registration is $35 (cash or check only).
Topic Description
Feb. 7, 2008
2
Herceptin almost failed to be developed because of a lack of vision by many but a few
diehard scientists and cancer activists. Following the initial discovery of cellular
oncogenes it took almost two decades the expertise and vision needed develop a drug
targeting a cellular form of an oncogene, Her2, to create Herceptin. The 20-year timeline
was influenced by the rise of new way of thinking about antibodies as therapies, a fuller
understanding of the mechanism behind some types of breast cancer, and all this was
accompanied by near heroic persistence by academic physician at UCLA and scientists at
Genentech.
Additional technology had to be developed prior to treating patients as well. Following
the development of monoclonal antibodies additional technologies that were required
included:
 Sensitive IHC/FISH
 Protein modeling and engineering
 Humanization of antibodies
 Rapid (< 1 month) protein production methods in mammalian cells
The mantra “binding is not enough” was one take home message following the success of
Herceptin but equally important the development of Herceptin carries with it a message
of doggedly pursuing something when you believe it strongly. Hear the story of how one
of biotech's most significant breakthrough drugs came into being despite many naysayers.
The next generation of Her2 therapeutics, including HER2 vaccines, will also be
summarized.
Speaker Bio
Dr. Gorman is an entrepreneur, strategist, and research scientist with experience in
business and drug development aspects of biotechnology industry. She has an outstanding
record of achievement in basic research and drug development in diverse areas including
gene therapy, gene expression and transfer, hormone processing, cell biology, protein
transport, and the humanization of antibodies and production of recombination of
proteins. At Genentech, Dr. Gorman played a key role in the development of a number of
marketed products including Kogenate, Activase, Hercepin, Xolair, and Raptiva. She also
played a role the early stages of Avastin. Based on her work at Genentech, Cori is also
recognized as a pioneer in the development of monoclonal antibody therapeutics and has
co-authored 6 INDs. An experienced entrepreneur, Cori has worked in all aspects of startup company, including raising capital, strategic planning, recruiting scientists, and
developing infrastructure. Her contributions were key to enabling Valentis, a gene
therapy company, to proceed to a successful IPO. Dr. Gorman has a strong publication
and presentation record and is an inventor on several issued patents in the fields of gene
expression and delivery and gene therapy. Dr. Gorman is also experienced in business
development having closed eighteen corporate partnerships for clients over a two-year
period. Early in her career Dr. Gorman was a recipient of several fellowships from the
American Cancer Society, the National Cancer Institute, the European Molecular Biology
Organization and NATO. She has be recognized for her teaching excellence and has been
an recurring invited lecturer at the University Colorado Health Sciences educating
physicians in molecular aspects of disease as well as a guest lecturer in the biotechnology
Feb. 7, 2008
3
program at Yale. Cori is recognized by citation index as one of the most highly cited
authors in the past two decades, with over 10,000 citations.
Haas Business School Health Care Conference, All Day Saturday, Feb. 9, 2008
Topic: Business of Health Care
Date and Time: Saturday, Feb 9
Registration and Information: http://www.haashealthcareconference.org
Cost: General Admission: $105
A limited number of tickets are available at special rates:
 UC Berkeley Alumni/Faculty/Staff: $75
 Current student at any university: $35
 Current H2B2 Club Members: $25
Register now! Tickets will sell out.
BayBio Medical Device Breakfast, Tuesday Morning, Feb. 12, 2008
Topic: When is it time to sell?”
 Panel Moderator: Frank F. Rahmani, Partner, Cooley Godward Kronish LLP
 Panel Speakers:
David Clapper, Chief Executive Officer, SurgRx; former CEO of Novacept
(sold to Cytyc)
 Jeff Gold, Venture Partner, Longitude Capital; former CEO of CryoVascular
Systems (sold to Boston Scientific Corporation
 Jay Watkins , Managing Director, De Novo Ventures; Co-founder of Origin
Medsystems (sold to Eli Lilly & Company)
Date and Time: Feb. 12, 8:00 am – 10:00 am
Location: Cooley Godward Kronish LLP, Palo Alto, CA Directions.
Attire: Business Attire Suggested
Topic Description
"When is it time to sell?" Whether you are the founder of a medical device company with
a product in development or the executive of a company with products in the market, the
issue of when and if to sell is often the most pivotal question faced by the entrepreneurs
and the executives, board members and stockholders of any company.
As the overall costs associated with product development, clinical studies, regulatory
approval process, and commercialization have steadily increased in the past several years,
the capital and funding requirements for medical device companies have also increased.
Entrepreneurs and existing investors are often faced with the issue of whether they should
seek additional capital and incur the inherent dilution and other issues associated with a
new round of funding or to seek the outright sale of the company. In recent years, the IPO
market has been used by some medical device companies as a means to raise additional
capital while ultimately providing some liquidity to existing investors. In addition, many
companies have utilized strategic partnerships and alliances as a means of defraying the
costs, and potentially accelerating the timelines, associated with product development and
Feb. 7, 2008
4
commercialization. Some companies have pursued a 'dual-path' strategy of pursuing an
IPO while at the same time engaging in strategic discussions in an effort to potentially
maximize the returns to stockholders.
The panel of experts will explore the key issues and considerations in whether or not to
sell the company, and share their experiences in an open round-table format. The
following will be among the topics explored: What are the best and worse reasons for
considering the sale of the company? What successes & failures are we seeing? What are
some industry trends affecting the medical device M&A landscape? What are some of the
key consideration from the founders' or management's standpoint? What are the
alternatives to an outright sale of the company?
Registrations:
On-line reservations: CLICK HERE
Reservations by mail or fax: CLICK HERE
Early Bird Registration through February 11, 2008:
$10.00 BayBio Members
$25.00 Non-Members
On-Site Registration, February 12, 2008:
$20.00 BayBio Members
$40.00 Non-Members
Bio2Device Group, Tuesday Evening Meeting, Feb. 12, 2008
Topic: “The Aragon Surgical LapCap acquisition: was this "Series A"
company crazy?”
Speaker: Christine Cunningham, Vice President, Marketing & Business Development
Date and time: Tuesday evening, Feb. 12, 6-9 pm
Location: KeyPoint Credit Union, 2805 Bowers Ave., Santa, Clara, CA
NO DAYTIME MEETING
Register thru Acteva <http://www.acteva.com/booking.cfm?bevaID=151378>
by midnight on Feb.10 to take advantage of a lower registration fee.
Company Background
Aragon Surgical is a venture backed, market driven surgical device company that is
developing and commercializing a variety of surgical instruments intended to reduce
operative time and improve patient safety, benefiting both patients and surgeons. Aragon
Surgical has been
awarded first place in the prestigious Daniel F. Kott competition at the 36th AAGL
Global Congress of Minimally Invasive Gynecology Meeting in Washington, D.C.
As the initial step in the majority of laparoscopic procedures, gynecologists and general
surgeons blindly pass a 12cm-long needle through the patient's abdominal wall and into
the abdominal cavity, guided only by subtle, tactile feedback. Correctly positioned, the
needle serves as the conduit for instillation of gas into the cavity, creating a
Feb. 7, 2008
5
"pneumoperitoneum" (the gas-filled space in which laparoscopic surgery is performed).
Unfortunately, blind needle passage is an inconsistent maneuver associated with risk of
needle injury (to intestines and vessels), patient death, and failure to initially correctly
position the needle (increasing patient risk and operative
time).
With the Aragon Surgical LapCap, blind needle passage is safe, simple,
rapid, and predictable. The novel device utilizes simple suction to
rapidly elevate the abdominal wall up and away from the intestines and
blood vessels, creating a "safe space" within the peritoneal
cavity into which the needle is passed.
Speaker Biography
Christine Cunningham brings to Aragon Surgical more than 20 years of experience in
international and domestic marketing, sales, and business development, both in the
medical device and pharmaceutical industries. Her extensive medical device experience
includes both diagnostics and therapeutics.
Christine began her career as a pharmaceutical sales representative for Sanofi Winthrop
Pharmaceuticals before joining Syntex Pharmaceuticals in a marketing capacity. At the
same time, she earned her M.B.A. Christine subsequently transitioned to the medical
device arena, joining MedaSonics, Inc. and advancing to Vice President of Sales &
Marketing. She subsequently joined Nellcor, Inc., entering as Market Development
Manager and then receiving promotion to Director of Strategy and Business
Development and ultimately serving as Senior Director of Marketing for Nellcor's entire
pulse oximetry business. Following Nellcor's acquisition by Tyco Healthcare, Christine
joined Novasys Medical, Inc., where for four years she served as Vice President of
Marketing and guiding the company from early market development through
product launch. She then joined newly funded Aragon Surgical, Inc., where she serves as
Vice President of Marketing and Business Development.
In addition to her work, Christine recently served two terms as President of the non-profit
Professional Women's Healthcare Alliance (PWHA) and is currently on their board. She
continues to teach marketing at the University of Phoenix.Topic.
San Francisco AWIS, Wednesday Evening, Feb. 13, 2008
Topic: “Hidden and Not So Hidden Biases in Clinical Research”
Date and Time: Weds, Feb 13, 6:30-8:00 PM
Location: Genentech Inc, Bldg 83 Rm 1A, 611 Gateway Blvd, South San Francisco
Cost: $10 general admission
$5 members/students/postdocs
Join us as UCSF's Lisa Bero shares stories from her professional and personal career
path, which uniquely spans basic and clinical research in some of today's most
controversial health policy issues.
Feb. 7, 2008
6
Speaker Bio
Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and
Institute for Health Policy Studies, School of Medicine, University of California, San
Francisco, is a pharmacologist with primary interests in how clinical and basic sciences
are translated into clinical practice and health policy. Her research includes developing
and validating methods for assessing the quality of research and scientific publication and
measuring influences on the quality of research. Dr. Bero also examines the
dissemination and policy implications of scientific research. She studies the roles of
interest groups and financial ties in influencing research and its dissemination. She has
published numerous peer-reviewed scientific articles related to her research and coauthored The Cigarette Papers (UC Press, 1996). Her international activities include:
advisor to the World Health Organization, senior editor for Tobacco Control, Co-Director
of the San Francisco Branch of the United States Cochrane Center, and editor for the
Cochrane Effective Practice and Organization of Care Group -- an international group of
researchers conducting meta-analyses of the literature on interventions to change health
professional behavior. She has also been elected as a member of the Cochrane
Collaboration Steering Group and serves on several national and international committees
related to conflict of interest or technology assessment.
All scientists, students, and friends welcome!
http://www.sfawis.com/
Bioscience Product Marketing, Feb. 14-March 13 and 27, 2008
Thursday Evenings starting Feb. 14 at 6:00 pm to 9:30 pm
Location: UCSC Extension in Silicon Valley, 10420 Bubb Rd., Cupertino
Fee: $700
This course introduces participants to the unique field of bioscience marketing. It
explores how biotech marketing differs from that of other industries, and introduces the
basic skills used in the development and implementation of biotech marketing programs.
Topics include:
· Overview of the bioscience industry
· Market-research methodologies and applications
· Development of marketing strategy, product-positioning plans and claim structure
· Tactical marketing programs and activities
Participants learn strategic planning and research skills relevant to marketing-research
and product-management functions in a biotech company and learn about the function of
marketing and its important role in building a successful bioscience company.
Participants explore the role and functions of biotech marketing staff in providing
strategic marketing, product planning and tactical marketing programs that specifically
support bioscience products and technology.
Course activities include integrated weekly assignments and a team project—all leading
to a team–developed product marketing plan presentation the last night. Participants
learn the skills and the process of team-based marketing planning and execution.
Feb. 7, 2008
7
Instructor: Audrey Erbes, Ph.D., is a marketing professional with more than 25 years of
managerial experience in marketing and business development in the biotech and
pharmaceutical industries.
Guest Speakers:
 Laura Raynak, C.M.C., principal of Raynak Search, a retained search firm, has
over 15 years of successful biotech and high tech executive search, corporate
staffing, sales, marketing and management experience.
 Stanley Skrzypczak, M.B.A., Director, Managed Care Marketing, Genomic
Health, has over 25 years of successful biotech and pharmaceutical sales and
marketing experience, including product, managed care, clinical marketing and
sales management.
 Charles Versaggi, Ph.D., is president of Versaggi Biocommunications®, a
strategic marketing consultancy for biotechnology, pharmaceutical and medical
technology companies.
 Steven Wong is a senior consultant at Plan A, a strategic marketing consulting
firm servicing biotechnology and pharmaceutical companies.
Please see www.ucsc-extension.edu/biobusiness for additional course information, or
email: program@ucsc-extension.edu.
Bio2Device Group, Tuesday Morning, Feb. 19, 2008
Speaker: Tony Clark, Asteame Medical Devices
Topic: TBD
Date and Time: Tuesday, Feb. 19, 8:30 am to 10:30 am
Location: NOVA, 505 West Olive, Sunnyvale, Room 510
Cost: Free
See details at www.bio2devicegroup.org
Fountain Blue Life Science Entrepreneurs Forum, Tuesday Evening, Feb. 19, 2008
Topic: “Incubating Life Science Companies”
Panel:
The panel of life science entrepreneurs represent early stage, funded and
public companies, each of whom interacted with SRI International.
* Facilitator Ted Spack, SRI International
* Panelist Melinda Richter, Executive Director, San Jose Biocenter
* Panelist Jim Rurka, co-founder of Blanca Pharmaceuticals
* Panelist Dave Yeomans, Trigemina Inc.
* Other Panelists to be confirmed
Date and Time: Feb. 19, 2008, 5:30 - 7:30 p.m.
Location: DLA Piper, 2000 University, East Palo Alto, CA.
Theme:
For 100 years, SRI International and other organizations in the valley have
Feb. 7, 2008
8
incubated technology, energy and life science companies, in partnership with
the business community and academia. SRI International and others will highlight their
success
stories from their incubated life science companies and find out:
* the range of companies which have graduated from SRI,
* factors for success
* the process for incubating and spinning out companies
* how foundation technologies from SRI-incubated companies are
impacting today's life science community
* and other points of interest.
Information and Registration: NO SERVICE PROVIDERS PLEASE.
* To pre-register now for the discounted rate of $18-$30, visit
http://www.acteva.com/booking.cfm?bevaid=146090 by noon on Friday, February
16. A limited amount of on-site registration is available for $40, on a
first-come, first-served basis.
PWC’s Shaking the Money Tree, Wednesday Morning, Feb. 20,
Event Topic: “Shaking the Money Tree”
Moderator:
Steve Bengston, PricewaterhouseCoopers
Panelists:
Sam Coates, Cooley Godward Kronish LLP
Jim DeMers, Lincoln funds, LSA
Shomit Ghose, Onset
Heidi Huntsman, UV Partners
Doug Kelly, Alloy Ventures
John Steuart, Claremont Creek
Date and Time: February 20, 7:30 - 9:30 a.m.
Location: Cooley Godward Kronish LLP
3175 Hanover Street, Palo Alto
Cost: $30
Sponsoring Group: PriceWaterhouseCoopers
Registration: rena.marichalar@us.pwc.com.
Bio Science Forum, Wednesday Evening, Feb. 20, 2008
Topic: TBA
Speaker: J. Kevin Judice, Ph.D., Chief Executive Officer, Achaogen
Date and Time: Wednesday, Feb. 20, 2008
6:00 pm – networking
7:00 pm – buffet dinner
8:00 pm - presentation
Location The Clarion Hotel, 401 East Millbrae Avenue, Millbrae, CA, 650-692-6363
See details at www.biosf.org
Feb. 7, 2008
9
IEEE Engineering in Medicine and Biology Society (EMBS) , Santa Clara Valley
Chapter , Evening Feb. 20
Topic: Starting and Building a Winning Medtech Business
Speaker: J. Casey McGlynn, Wilson Sonsini Goodrich & Rosati
Date and time: Wednesday, February 20, 2008, 7:30pm
Location: Clark Center Auditorium at Stanford University, Palo Alto
Optional Dinner, Stanford Hospital Cafeteria, 6:15pm (no reservations)
Topic Description
This talk will focus on starting and building a winning medtech business. Among other
topics, it will address:
a... The Idea. How do you get your idea out of the university and into a company? What
types of ideas are most fundable? What do you need to do to protect your idea, and what
things can wait until after funding?
b... Funding. Is angel or venture capital the best way to go? How developed does the idea
need to be in order to attract capital? What are some successful strategies for finding
money? How should the investment be structured?
c... The Team. What members of the team are needed to get the enterprise started? Where
do you go to find the right people?
d... Growing the Business. How do you go about building a winning culture? How do you
make sure the enterprise is capital efficient? How should you manage you board?
e... Selling the Business. What are some successful strategies in selling your business?
How should the deal be structured?
Speaker Bio
J. Casey McGlynn joined Wilson Sonsini Goodrich & Rosati in 1978 and formed the Life
Sciences Group at the firm in 1990. It is a nationally recognized leader in the
representation of startup and emerging growth companies in the life sciences field. Mr.
McGlynn has one of the largest practices in the country focused on Medical Devices.
Mr. McGlynn has formed, sold and taken public many of the most important medical
device companies started during the last 25 years. These companies include Anatros
Corporation (predecessor to Tyco's IV business), Advanced Cardiovascular Systems and
Devices for Vascular Interventions (predecessors to Guidant's vascular business, now
Abbott Vascular), Aneurx (predecessor to Medtronic's Aortic Aneurism business),
Arthrocare (ARTC), Biopsys Medical (predecessor to JNJ's women's health business),
Cardiac Pathways (now part of BSX's EP catheter business), Cardiothoracic Systems
(predecessor to Guidant's cardiac surgery business), Conor MedSystems (now part of
Cordis/JNJ), Cutera (CUTR), CVIS (predecessor to BSX's vascular ultrasound business),
FoxHollow Technologies (now part of ev3's peripheral vascular business), Fusion
Medical (predecessor to Baxter's surgical sealant business), HeartStream (predecessor to
Phillips' external defibrillator business), Kyphon (acquired by Medtronic), Perclose
(predecessor to Abbott's vascular closure business), Somnus Medical (predecessor to
Gyrus' ENT business), Spinal Concepts (predecessor to Abbott's orthopedics business),
Feb. 7, 2008
10
Ventana Medical Systems (VMSI), and Ventritex (predecessor to St Jude's CRM
business).
See http://ieee.org/scv/embs for details.
Palo Alto AWIS, Thursday Evening, Feb. 21, 2008
Topic: “How to Get Out of Your Own Way: Optimism as a Career Strategy”
Speaker: Kimberly Wiefling, Founder, wiefling Consulting and Author, Scrappy Project
Management
Date and Time: Thursday, Feb. 21, 7:00 to 9:00 pm
Location: PARC Auditorium, 3333 Coyote Hill Road , Palo Alto
Free, RSVP: http://www.acteva.com/booking.cfm?bevaid=149031
Description of Lecture
‘Perception is Reality’, and we’ll explore how to powerfully reframe situations and
events in order to increase our professional and personal effectiveness. This highly
interactive and engaging event incorporates techniques of improv, role-play, creativity,
and breakthrough thinking that will enable you to set and achieve goals that initially seem
highly unlikely or nearly impossible (her specialty!).
Speaker Bio
Kimberly has gained international acclaim for her enthusiasm-infused leadership
programs, her project management workshops, and her recently published book Scrappy
Project Management (which she can sign for you!).
She facilitates seminars for executives on these topics all over the world, most recently in
the US, Europe and Japan. A physicist and chemist by education, she has 10 years of
experience with HP, 5 years with start-ups, and the past 7 years running her own
consulting company. She’ll tap into her 20 years of experience working in technical
fields among scientists and engineers to help us gain new perspectives on professional
development and career paths.
Before the talk, there will be a special book signing by Catherine Brady, author of
"Elizabeth Blackburn, and the Story of Telomeres", about a distinguished local scientist.
Welcome!! This Meeting is free. You don't need to be a member to attend.
All scientists, students, and their friends are welcome. Men too!
Bio2Device Group, Tuesday Morning, Feb. 26, 2008
Speaker: TBD
Topic: TBD
Date and Time: Tuesday, Jan. 29, 8:30 am to 10:30 am
Location: NOVA, 505 West Olive, Sunnyvale, Room 510
Cost: Free
See details at www.bio2devicegroup.org
Feb. 7, 2008
11
TIE Life Sciences, Wednesday Evening, Feb. 27, 2008
Topic: Between a Rock & a Hard Place: Highly Experienced Biotech CEOs Tell It Like
It Was, Is & May Be Going Forward!!
Date and Time: Wednesday, Feb. 27, 5 pm-9 pm
5:00 PM – Cocktails and Networking
6:00 pm – Dinner
6:30 pm – Interactive Panel & Q&A
8:00 pm – The Nightcap
9:00 pm – Close
Location Gilead Sciences, Inc., 322 Lakeside Dr., Foster City, CA
Cost: $50 for nonmembers online and $60 at event
$35 for members online and $45 at event
Register at https://www.123signup.com/register?id=tqjxt
Event Host : Nandini Tandon, TiE SV Charter Member
Moderator : Bruce Jenett, Heller Ehrman
Panelists
Gail Maderis President and Chief Executive Officer, Five Prime Therapeutics
Jack Anthony Chief Executive Officer,Osprey Pharmaceuticals
Steven James President, Chief Executive Officer, KAI Pharmaceuticals, Inc.
Tom King President, Chief Executive Officer, Alexza Pharmaceuticals, Inc.
Note Arlene Morris of Affymax not speaking as indicated in other locations
Registration closes at 12 Noon on the day of the event & No Refunds are issued for
cancellations
Topic Description
The role of the Biotech CEO has evolved over the years from the visionary few, who
were charting new business models, with investors just beginning to understand the world
of biotech, to today where the CEOs are veterans in the industry and have worked their
way up to this leadership position, in markets good, bad and ugly.
What spectrum of experience prepared them for this role? What memories do they
cherish and which ones would they rather forget? What might they have done differently
if they could revisit their past? Guided with what personal mantra do they approach their
responsibilities, in their day to day role and also in their larger vision?
Join in an interactive session to learn firsthand of their thoughts, war stories & insights.
Feb. 7, 2008
12
Feb. 1, 2008
13